{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(1)"],"submitter":["Harrasser M"],"funding":["National Institute for Health Research (NIHR) Blood and Transplant Research Unit","Kay Kendall Leukaemia Fund","NHS Blood and Transplant","National Institute for Health Research (NIHR)","Wellcome Trust"],"pubmed_abstract":["<h4>Background</h4>Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosuppressive tumor microenvironment (TME) which limits the activity of tumor-infiltrating lymphocytes (TILs) including CAR-T cells. We have developed a next-generation armored CAR (F i-CAR) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is expressed at high levels in a range of aggressive tumors including poorly prognostic triple-negative breast cancer (TNBC). The F i-CAR-T is designed to release an anti-PD-1 checkpoint inhibitor upon CAR-T cell activation within the TME, facilitating activation of CAR-T cells and TILs while limiting toxicity.<h4"],"journal":["Breast cancer research : BCR"],"pagination":["39"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9166313"],"repository":["biostudies-literature"],"pubmed_title":["Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC."],"pmcid":["PMC9166313"],"pubmed_authors":["Grigoriadis K","Harrasser M","Evans R","Lau H","Patel D","Gohil SH","Muczynski V","Granger D","Della Peruta M","Grigoriadis A","Nathwani AC","Miranda E"],"additional_accession":[]},"is_claimable":false,"name":"Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.","description":"<h4>Background</h4>Chimeric antigen receptor (CAR)-T cells can induce powerful immune responses in patients with hematological malignancies but have had limited success against solid tumors. This is in part due to the immunosuppressive tumor microenvironment (TME) which limits the activity of tumor-infiltrating lymphocytes (TILs) including CAR-T cells. We have developed a next-generation armored CAR (F i-CAR) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is expressed at high levels in a range of aggressive tumors including poorly prognostic triple-negative breast cancer (TNBC). The F i-CAR-T is designed to release an anti-PD-1 checkpoint inhibitor upon CAR-T cell activation within the TME, facilitating activation of CAR-T cells and TILs while limiting toxicity.<h4","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-25T19:08:07.474Z","creation":"2025-04-06T07:50:12.68Z"},"accession":"S-EPMC9166313","cross_references":{"pubmed":["35659040"],"doi":["10.1186/s13058-022-01531-1"]}}